Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders to September 11, 2025, to allow for broader participation. The Board of Directors recommends voting FOR proposals outlined in the Proxy Statement. Stockholders can vote online or by mail, with deadlines on September 10, 2025. The company’s lead product, the DurAVR® Transcatheter Heart Valve, is designed to treat aortic stenosis. Anteris is committed to restoring healthy heart function with cutting-edge medical devices. Forward-looking statements caution readers about risks and uncertainties related to the Special Meeting. For more information, contact Investor Relations.

Read more at GlobeNewswire: Anteris Technologies Global Corp. Announces Postponement of